Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health
Business Wire•18/11/2026•09:00 ET
15
Key Highlights
- ➤Hims & Hers (HIMS) launches Peptides+ with five U.S.-compounded treatments
- ➤Peptides+ requires licensed-provider clinical visits and personalized treatment plans
- ➤Care+ includes twice-yearly lab testing, unlimited support, and 24/7 provider messaging
- ➤Hims & Hers plans BPC-157 and TB-500 access, subject to regulatory standards
Expert Statements
Anant Vinjamoori, Chief Medical Officer of Hims
“Peptides+ gives men a clinically guided, personalized plan built around their goals, backed by a licensed provider who understands these therapies”
Anant Vinjamoori, Chief Medical Officer of Hims
“Anyone investing in their health deserves to know exactly what they’re putting in their body, and to have dedicated support along the way.”
Jessica Shepherd, Chief Medical Officer of Hers
“Women are used to being told their fatigue, brain fog, and changing bodies are simply part of life, and many have had to advocate for themselves just to be heard”
Jessica Shepherd, Chief Medical Officer of Hers
“We believe women deserve a more comprehensive and personalized approach to their health, one that considers their unique health history, evolving needs and individual goals.”
Jessica Shepherd, Chief Medical Officer of Hers
“The emerging therapies in Peptides+ have exciting potential.”
Jessica Shepherd, Chief Medical Officer of Hers
“Meaningful outcomes start with understanding the whole person, making informed, evidence-based decisions and ensuring women have trusted medical guidance and ongoing support at every stage of life.”
Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health
A new specialty built to support each person’s unique, ever-changing biology, with real medical leadership at every step
Get started
Create a free account to read the full story.
